MRTX News and Press, Mirati Therapeutics Inc. From 05/24/23

Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO® PR Newswire SAN DIEGO , May 24, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial-stage oncology co...

2023-05-20 04:46:48 ET Summary Mirati Therapeutics has achieved significant success with its FDA-approved cancer drug, Krazati, but the company's recent financials reveal potential challenges ahead. Despite earning $6.3M in product revenue from Krazati in Q1 2023, rising operation...

2023-05-09 22:44:09 ET Mirati Therapeutics, Inc. (MRTX) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants Ryan Asay – Vice President-Corporate Affairs David Meek – Chief Executive Officer Ben Hickey – Chief Commerci...

2023-05-09 16:30:54 ET Mirati Therapeutics press release ( NASDAQ: MRTX ): Q1 GAAP EPS of -$3.18 beats by $0.41 . Revenue of $7.17M (+909.9% Y/Y) beats by $2.37M . Net reduction in cash, cash equivalents and short-term investments for the first quarter was $181...

Mirati Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Updates PR Newswire SAN DIEGO , May 9, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced fi...

2023-05-08 17:35:56 ET Major earnings expected after the bell on Tuesday include: Airbnb ( ABNB ) Occidental Petroleum Corporation ( OXY ) Twilio ( TWLO ) Virgin Galactic Holdings ( SPCE ) Upstart Holdings ( UPST ) For further details see: ...

Mirati Therapeutics and Sarah Cannon Research Institute Announce Strategic, Community Site Focused Partnership to Increase Diversity in Oncology Clinical Studies PR Newswire SAN DIEGO and NASHVILLE, Tenn. , May 8, 2023 /PRNewswire/ -- Mirati Therapeutics, I...

2023-04-27 18:01:59 ET Gainers: Mirati Therapeutics ( MRTX ) +10% . JAKKS Pacific ( JAKK ) +10% . Amazon.com ( AMZN ) +9% . Datadog ( DDOG ) +8% . Recursion Pharmaceuticals ( RXRX ) +6% . Losers: Accolade ( ACCD ) -...

Mirati Therapeutics to Participate at the Bank of America Securities 2023 Health Care Conference PR Newswire SAN DIEGO , April 27, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, will partici...

Journal of Clinical Oncology Publishes Rapid Communication Featuring Updated Clinical Data for Adagrasib as a Targeted Treatment for KRASG12C-Mutated Advanced Solid Tumors PR Newswire Data demonstrates compelling clinical activity, highlights adagrasib potential as monothera...